Physiomics (PYC)

 

PYC Share PerformanceMore

52 week high4.9000 28/04/16
52 week low1.2050 28/02/17
52 week change -2.2250 (-63.57%)
4 week volume10,341,943 02/03/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Physiomics' losses rise

Physiomics has reported an operating loss of 263,509 for the six month period ended 31 December, compared to a restated lo...

Interim Results Statement

RNS Number: 4688A Physiomics PLC 24 March 2017 Physiomics Plc ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2016 Oxford, UK, 24 March 2017: The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces its financial results for the six months ended 31 December 2...

Physiomics makes good progress on strategic objectives

Physiomics anticipates that in H1 of its current financial year revenues will be broadly in line with the comparable period...

Company Update

RNS Number: 8389T Physiomics PLC 11 January 2017 Physiomics plc ("Physiomics") or ("the Company") Company Update Physiomics plc (AIM: PYC) is pleased to announce that it is making good progress towards the strategic objectives announced in its most recent full year results (RNS 27 th October 2016 and subsequent printed annual report circulated to shareho...

Physiomics confirms award of Innovate UK grant

Physiomics confirm that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibility Stu...

Confirmation of Award of Innovate UK Grant

RNS Number: 4882T Physiomics PLC 06 January 2017 6 th January 2017 Physiomics plc ("Physiomics") or ("the Company") Confirmation of Award of Innovate UK Grant Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to confirm that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibili...

Director Deals - Physiomics PLC (PYC)

Dr James Millen, Chief Executive Officer, bought 200,000 shares in the company on the 22nd December 2016 at a price of...

Director Dealing

RNS Number: 6506S Physiomics PLC 22 December 2016 Physiomics plc ("Physiomics" or the "Company") Director Dealing The Company announces that it received notice today that Dr Jim Millen, the Company's CEO, has purchased a total of 200,000 ordinary shares in the Company at a price of 2.5p per share, being the most recent placing price, as announced on 2...

Fundamental DataMore

EPS-0.01
Dividend yield0 %

Equity Research (PYC)

Physiomics plc
24/03/2017
The computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients...
Physiomics plc
17/01/2017
The computational systems biology services Company applying simulations of cell behaviour to drug development recently provided an update. It declared good progress on its strategic objectives...
Physiomics plc
01/11/2016
Following the decision not to proceed with the acquisition of oncology therapeutics Company BioMoti, Physiomics is now 100% focused on growing the revenues and creating a path to profitability in the...

Latest discussion posts More

  • 1/100 consolidation

    proposed for the 16th December
    24-Nov-2016
    1timco
  • auction

    gla :D
    9-Sep-2016
    etadelete
  • take off

    get in.sar on the move.could be news soon.gla
    21-Mar-2016
    etadelete

Users' HoldingsMore

Users who hold Physiomics also hold..
SAREUM20%
SOLO OIL19%
LLOYDS GRP.17%
RANGE RES.16%
VICTORIA OIL16%

Codes & Symbols

ISINGB00BDR6W943
SymbolsPYC, LSE:PYC, PYC.L, PYC:LN, LON:PYC, XLON:PYC